Contents hide 1 About Furmonertinib 2 Approval 3 Dosage 3.1 Dosage adjustment About Furmonertinib Furmonertinib Mesilate acts as an anti-cancer agent. It is formulated as tablets for oral route of administration. Furmonertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation. Furmonertinib sold under the brand name Ivesa.  Furmonertinib sold under the brand name 艾弗沙 in china. Approval June/2022, Shanghai Allist Pharmaceuticals Co., Ltd. (stock code: 688578) announced that Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China for use in the … Continue reading Ivesa (Furmonertinib)